{"success":true,"data":{"pressRelease":{"id":"157398","rtpr_id":"nNFC4wVYRR-20260930","ticker":"VIVI","exchange":"","all_tickers":["VIVI"],"title":"TempraMed Technologies Ltd. Announces Closing of Private Placement","author":"Newsfile Corp","published_at":"2026-09-30T22:00:21.265Z","article_body":"Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed\nTechnologies Ltd. (CSE: VIVI) (\"TempraMed\" or the \"Company\"), is pleased to\nannounce that, further to its September 23, 2026 and September 28, 2026 news\nreleases, it has closed its non-brokered private placement (the \"Offering\") of\nunsecured convertible debentures of the Company (each, a \"Convertible\nDebenture\") and units (each, a \"Unit\"). The Company issued $600,000 of\nprincipal amount of Convertible Debentures and 1,155,880 Units under the\nOffering for gross aggregate proceeds of $1,177,940.\n\nEach Unit issued under the Offering consists of one common share in the\ncapital of the Company (each, a \"Common Share\") and one Common Share purchase\nwarrant of the Company (each, a \"Warrant\"). Each Warrant will entitle the\nholder thereof to purchase one additional Common Share at a price of C$1.00\n(each, a \"Warrant Share\") at any time on or before March 30, 2028.\n\nThe Convertible Debentures issued under the Offering bear interest at a rate\nof 10% per annum, calculated monthly and payable quarterly in cash. The\nConvertible Debentures issued under of the Offering will mature on September\n30, 2027 (the \"Maturity Date\"). The outstanding principal amount owed under\neach Convertible Debenture may be converted into Common Shares at a conversion\nprice of $0.50 per Common Share (the \"Conversion Price\") by the holder thereof\nat any time on or before the Maturity Date.\n\nThe use of proceeds from the Offering will fund new inventory, product\ndevelopment, and to scale the sales and marketing division globally, as well\nas general working capital.\n\nIn connection with the Offering, the Company paid an aggregate of $40,456 in\nfinder's fees to certain qualified arm's length parties (each, a \"Finder\"), as\nwell as issuing 80,912 Common Shares to such Finders.\n\nAll securities issued in connection with the Offering, including any Warrant\nShares, are subject to a restricted period of four months and one day from\nclosing of the Offering.\n\nThe securities of the Company referred to in this press release have not been\nand will not be registered under the United States Securities Act of 1933, as\namended (the \"U.S. Securities Act\"), or any state securities laws.\nAccordingly, the securities of the Company may not be offered or sold within\nthe United States unless registered under the U.S. Securities Act and\napplicable state securities laws or pursuant to an exemption from the\nregistration requirements of the U.S. Securities Act and applicable state\nsecurities laws. This news release does not constitute an offer to sell or a\nsolicitation of any offer to buy any securities of the Company in any\njurisdiction in which such offer, solicitation or sale would be unlawful.\n\nAbout TempraMed Technologies Ltd.\n\nTempraMed Technologies Ltd. is a global medical-device company with a\nportfolio of innovative, temperature-controlled medication storage solutions.\nFounded with the mission to safeguard the effectiveness of life-saving\nmedications, TempraMed develops patented, FDA-registered thermal insulation\ndevices that work 24/7 without batteries or external power. With a product\nline already in market including VIVI Cap™, VIVI Cap Smart™, VIVI Epi™\nand VIVI Med™, TempraMed enables patients and healthcare providers to\nconfidently manage temperature-sensitive medications anywhere, anytime. With\noperations in North America, Europe and Asia, TempraMed continues to expand\nglobally with solutions for medication protection and adherence.\n\nInvestors interested in learning more about TempraMed are encouraged to\ncontact the Company at:\n\nir@tempramed.com\nwww.tempramed.com\n\nContact\n\nJulia Becker\nVice President, Capital Markets\nT: +1 (604) 785-0850\nE: julia@tempramed.com\n\nMedia\n\nBrenda Zeitlin\nVice President, Marketing\nE: brenda@tempramed.com\n\nCautionary Statement Regarding \"Forward-Looking\" Information\n\nThis News Release includes certain \"forward-looking statements\" which are not\ncomprised of historical facts. Forward-looking statements include estimates\nand statements that describe the Company's future plans, objectives or goals,\nincluding words to the effect that the Company or management expects a stated\ncondition or result to occur. Forward-looking statements may be identified by\nsuch terms as \"believes\", \"anticipates\", \"expects\", \"estimates\", \"may\",\n\"could\", \"would\", \"will\", \"likely\", \"probably\", \"often\", or \"plan\".\n\nSince forward-looking statements are based on assumptions and address future\nevents and conditions, by their very nature they involve inherent risks and\nuncertainties. Although these statements are based on information currently\navailable to the Company, the Company provides no assurance that actual\nresults will meet management's expectations. Risks, uncertainties and other\nfactors involved with forward-looking information could cause actual events,\nresults, performance, prospects and opportunities to differ materially from\nthose expressed or implied by such forward-looking information.\nForward-looking information in this news release includes, but is not limited\nto, the use of the proceeds from the Offering. Factors that could cause actual\nresults to differ materially from such forward-looking information include\nfluctuations in general macroeconomic conditions, fluctuations in securities\nmarkets, the ability of the Company to successfully achieve its business\nobjectives, the ability of the Company to satisfy stock exchange requirements\nin a timely manner. Additional factors and risks including various risk\nfactors discussed in the Company's disclosure documents which can be found\nunder the Company's profile on http://www.sedarplus.ca. Should one or more of\nthese risks or uncertainties materialize, or should assumptions underlying the\nforward-looking statements prove incorrect, actual results may vary materially\nfrom those described herein as intended, planned, anticipated, believed,\nestimated or expected.\n\nAlthough the forward-looking statements contained in this news release are\nbased upon what management of the Company believes, or believed at the time,\nto be reasonable assumptions, the Company cannot assure shareholders that\nactual results will be consistent with such forward-looking statements, as\nthere may be other factors that cause results not to be as anticipated,\nestimated or intended. Readers should not place undue reliance on the\nforward-looking statements and information contained in this news release.\nThese statements speak only as of the date of this news release. The Company\nassumes no obligation to update the forward-looking statements or beliefs,\nopinions, projections, or other factors, should they change, except as\nrequired by law.\n\nTHIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR\nDISSEMINATION IN THE UNITED STATES\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316845","article_body_html":"","raw_payload":{"data":{"id":"nNFC4wVYRR-20260930","title":"TempraMed Technologies Ltd. Announces Closing of Private Placement","author":"Newsfile Corp","ticker":"VIVI","created":"2026-09-30T22:00:21.265Z","tickers":["VIVI"],"exchange":"","article_body":"Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed\nTechnologies Ltd. (CSE: VIVI) (\"TempraMed\" or the \"Company\"), is pleased to\nannounce that, further to its September 23, 2026 and September 28, 2026 news\nreleases, it has closed its non-brokered private placement (the \"Offering\") of\nunsecured convertible debentures of the Company (each, a \"Convertible\nDebenture\") and units (each, a \"Unit\"). The Company issued $600,000 of\nprincipal amount of Convertible Debentures and 1,155,880 Units under the\nOffering for gross aggregate proceeds of $1,177,940.\n\nEach Unit issued under the Offering consists of one common share in the\ncapital of the Company (each, a \"Common Share\") and one Common Share purchase\nwarrant of the Company (each, a \"Warrant\"). Each Warrant will entitle the\nholder thereof to purchase one additional Common Share at a price of C$1.00\n(each, a \"Warrant Share\") at any time on or before March 30, 2028.\n\nThe Convertible Debentures issued under the Offering bear interest at a rate\nof 10% per annum, calculated monthly and payable quarterly in cash. The\nConvertible Debentures issued under of the Offering will mature on September\n30, 2027 (the \"Maturity Date\"). The outstanding principal amount owed under\neach Convertible Debenture may be converted into Common Shares at a conversion\nprice of $0.50 per Common Share (the \"Conversion Price\") by the holder thereof\nat any time on or before the Maturity Date.\n\nThe use of proceeds from the Offering will fund new inventory, product\ndevelopment, and to scale the sales and marketing division globally, as well\nas general working capital.\n\nIn connection with the Offering, the Company paid an aggregate of $40,456 in\nfinder's fees to certain qualified arm's length parties (each, a \"Finder\"), as\nwell as issuing 80,912 Common Shares to such Finders.\n\nAll securities issued in connection with the Offering, including any Warrant\nShares, are subject to a restricted period of four months and one day from\nclosing of the Offering.\n\nThe securities of the Company referred to in this press release have not been\nand will not be registered under the United States Securities Act of 1933, as\namended (the \"U.S. Securities Act\"), or any state securities laws.\nAccordingly, the securities of the Company may not be offered or sold within\nthe United States unless registered under the U.S. Securities Act and\napplicable state securities laws or pursuant to an exemption from the\nregistration requirements of the U.S. Securities Act and applicable state\nsecurities laws. This news release does not constitute an offer to sell or a\nsolicitation of any offer to buy any securities of the Company in any\njurisdiction in which such offer, solicitation or sale would be unlawful.\n\nAbout TempraMed Technologies Ltd.\n\nTempraMed Technologies Ltd. is a global medical-device company with a\nportfolio of innovative, temperature-controlled medication storage solutions.\nFounded with the mission to safeguard the effectiveness of life-saving\nmedications, TempraMed develops patented, FDA-registered thermal insulation\ndevices that work 24/7 without batteries or external power. With a product\nline already in market including VIVI Cap™, VIVI Cap Smart™, VIVI Epi™\nand VIVI Med™, TempraMed enables patients and healthcare providers to\nconfidently manage temperature-sensitive medications anywhere, anytime. With\noperations in North America, Europe and Asia, TempraMed continues to expand\nglobally with solutions for medication protection and adherence.\n\nInvestors interested in learning more about TempraMed are encouraged to\ncontact the Company at:\n\nir@tempramed.com\nwww.tempramed.com\n\nContact\n\nJulia Becker\nVice President, Capital Markets\nT: +1 (604) 785-0850\nE: julia@tempramed.com\n\nMedia\n\nBrenda Zeitlin\nVice President, Marketing\nE: brenda@tempramed.com\n\nCautionary Statement Regarding \"Forward-Looking\" Information\n\nThis News Release includes certain \"forward-looking statements\" which are not\ncomprised of historical facts. Forward-looking statements include estimates\nand statements that describe the Company's future plans, objectives or goals,\nincluding words to the effect that the Company or management expects a stated\ncondition or result to occur. Forward-looking statements may be identified by\nsuch terms as \"believes\", \"anticipates\", \"expects\", \"estimates\", \"may\",\n\"could\", \"would\", \"will\", \"likely\", \"probably\", \"often\", or \"plan\".\n\nSince forward-looking statements are based on assumptions and address future\nevents and conditions, by their very nature they involve inherent risks and\nuncertainties. Although these statements are based on information currently\navailable to the Company, the Company provides no assurance that actual\nresults will meet management's expectations. Risks, uncertainties and other\nfactors involved with forward-looking information could cause actual events,\nresults, performance, prospects and opportunities to differ materially from\nthose expressed or implied by such forward-looking information.\nForward-looking information in this news release includes, but is not limited\nto, the use of the proceeds from the Offering. Factors that could cause actual\nresults to differ materially from such forward-looking information include\nfluctuations in general macroeconomic conditions, fluctuations in securities\nmarkets, the ability of the Company to successfully achieve its business\nobjectives, the ability of the Company to satisfy stock exchange requirements\nin a timely manner. Additional factors and risks including various risk\nfactors discussed in the Company's disclosure documents which can be found\nunder the Company's profile on http://www.sedarplus.ca. Should one or more of\nthese risks or uncertainties materialize, or should assumptions underlying the\nforward-looking statements prove incorrect, actual results may vary materially\nfrom those described herein as intended, planned, anticipated, believed,\nestimated or expected.\n\nAlthough the forward-looking statements contained in this news release are\nbased upon what management of the Company believes, or believed at the time,\nto be reasonable assumptions, the Company cannot assure shareholders that\nactual results will be consistent with such forward-looking statements, as\nthere may be other factors that cause results not to be as anticipated,\nestimated or intended. Readers should not place undue reliance on the\nforward-looking statements and information contained in this news release.\nThese statements speak only as of the date of this news release. The Company\nassumes no obligation to update the forward-looking statements or beliefs,\nopinions, projections, or other factors, should they change, except as\nrequired by law.\n\nTHIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR\nDISSEMINATION IN THE UNITED STATES\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316845"},"type":"article","timestamp":"2026-09-30T22:00:21.319840518Z","server_sent_at_ms":1790805621319},"received_at":"2026-09-30T22:00:21.371Z","source_url":"https://www.newsfilecorp.com/release/316845"},"analysis":{"id":"146067","press_release_id":"157398","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["high-cost financing: 10% interest convertible debentures","conversion price of $0.50 and warrants at C$1.00 imply meaningful dilution overhang","proceeds partly earmarked for general working capital","gross proceeds (~$1.18M) are modest, suggesting limited access to larger capital"],"eventType":"offering","narrative":"TempraMed Technologies closed a non-brokered private placement of convertible debentures and units for gross proceeds of $1,177,940, including $600,000 of debenture principal and 1,155,880 units.\n\nThe debentures carry a 10% annual interest rate and mature September 30, 2027, convertible into shares at $0.50; each unit includes a share plus a warrant exercisable at C$1.00 until March 30, 2028.\n\nProceeds fund new inventory, product development, global sales and marketing, and working capital. The financing signals ongoing cash needs typical of a commercial-stage micro-cap medical-device company, with dilution risk if warrants and debentures are exercised.","sentiment":"mixed","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap closes small convertible private placement to fund inventory and global expansion."},"keyFigures":{"dealValueUsd":"$1,177,940","offeringPrice":"C$1.00 (warrant exercise price)","sharesOffered":1155880,"customDimensions":{"finders_fees":"$40,456","finder_shares":80912,"maturity_date":"September 30, 2027","warrant_expiry":"March 30, 2028","conversion_price":"$0.50","debenture_interest_rate":"10% per annum","convertible_debentures_principal":"$600,000"}},"namedEntities":{"people":[{"name":"Julia Becker","role":"Vice President, Capital Markets"},{"name":"Brenda Zeitlin","role":"Vice President, Marketing"}],"products":["VIVI Cap™","VIVI Cap Smart™","VIVI Epi™","VIVI Med™"],"companies":[{"name":"TempraMed Technologies Ltd.","ticker":"VIVI","relationship":"issuer"}],"dollarAmounts":[{"amount":"$600,000","context":"principal amount of convertible debentures issued"},{"amount":"$1,177,940","context":"gross aggregate proceeds of the offering"},{"amount":"C$1.00","context":"warrant exercise price"},{"amount":"$0.50","context":"debenture conversion price per common share"},{"amount":"$40,456","context":"aggregate finder's fees paid"}]},"materialImpact":{"score":2,"reasoning":"A small C$1.18M non-brokered private placement of convertible debentures and units by a micro-cap issuer. Provides working capital but adds 10% interest debt and share dilution via warrants and potential conversion."},"tickerRelevance":{"others":[],"primary":"VIVI"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":["debt_offering"],"importanceComponents":{"exchange":"CSE","tickerTier":"micro-cap","eventGravity":"small private placement","dilutiveNature":true}},"event_type":"offering","event_type_secondary":["debt_offering"],"sentiment":"mixed","material_impact_score":2,"narrative":"TempraMed Technologies closed a non-brokered private placement of convertible debentures and units for gross proceeds of $1,177,940, including $600,000 of debenture principal and 1,155,880 units.\n\nThe debentures carry a 10% annual interest rate and mature September 30, 2027, convertible into shares at $0.50; each unit includes a share plus a warrant exercisable at C$1.00 until March 30, 2028.\n\nProceeds fund new inventory, product development, global sales and marketing, and working capital. The financing signals ongoing cash needs typical of a commercial-stage micro-cap medical-device company, with dilution risk if warrants and debentures are exercised.","key_figures":{"dealValueUsd":"$1,177,940","offeringPrice":"C$1.00 (warrant exercise price)","sharesOffered":1155880,"customDimensions":{"finders_fees":"$40,456","finder_shares":80912,"maturity_date":"September 30, 2027","warrant_expiry":"March 30, 2028","conversion_price":"$0.50","debenture_interest_rate":"10% per annum","convertible_debentures_principal":"$600,000"}},"named_entities":{"people":[{"name":"Julia Becker","role":"Vice President, Capital Markets"},{"name":"Brenda Zeitlin","role":"Vice President, Marketing"}],"products":["VIVI Cap™","VIVI Cap Smart™","VIVI Epi™","VIVI Med™"],"companies":[{"name":"TempraMed Technologies Ltd.","ticker":"VIVI","relationship":"issuer"}],"dollarAmounts":[{"amount":"$600,000","context":"principal amount of convertible debentures issued"},{"amount":"$1,177,940","context":"gross aggregate proceeds of the offering"},{"amount":"C$1.00","context":"warrant exercise price"},{"amount":"$0.50","context":"debenture conversion price per common share"},{"amount":"$40,456","context":"aggregate finder's fees paid"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T22:00:27.094Z","global_importance":10,"audience_relevance":8,"importance_components":{"exchange":"CSE","tickerTier":"micro-cap","eventGravity":"small private placement","dilutiveNature":true}},"durationMs":5702,"modelName":"glm-5.3-flashx"}}